<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4CB92F40-4E51-4027-B354-8C9737DBBCAD"><gtr:id>4CB92F40-4E51-4027-B354-8C9737DBBCAD</gtr:id><gtr:name>University of Tromsoe</gtr:name><gtr:address><gtr:line1>Arctic University of Norway</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A919B771-5C0F-4AD1-B747-03D25677DC3B"><gtr:id>A919B771-5C0F-4AD1-B747-03D25677DC3B</gtr:id><gtr:name>University of Texas Southwestern Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FA04CA23-EB82-46AF-B73D-67FF08E5576E"><gtr:id>FA04CA23-EB82-46AF-B73D-67FF08E5576E</gtr:id><gtr:name>University of Ancona</gtr:name><gtr:address><gtr:line1>Faculty of Medicine</gtr:line1><gtr:postCode>I-60020</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC68D4D9-FDF1-4BA8-826F-1AF5D36C82CE"><gtr:id>FC68D4D9-FDF1-4BA8-826F-1AF5D36C82CE</gtr:id><gtr:name>Centre for Genomic Regulation (CRG)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F94E0EA2-DA20-4E08-9841-2A69C2FEA91D"><gtr:id>F94E0EA2-DA20-4E08-9841-2A69C2FEA91D</gtr:id><gtr:name>Institute for Molecular Medicine Finland</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/103D3F37-4066-444D-93DA-A10CF99F10F5"><gtr:id>103D3F37-4066-444D-93DA-A10CF99F10F5</gtr:id><gtr:name>Austrian Academy of Sciences</gtr:name><gtr:address><gtr:line1>Lazarettgasse 14</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F4DC8F58-AC06-4EB1-976C-EAA0136CC12F"><gtr:id>F4DC8F58-AC06-4EB1-976C-EAA0136CC12F</gtr:id><gtr:name>Museu da Lourinh?</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/39C210D7-B8AA-4A08-A580-FEAB7BACD30E"><gtr:id>39C210D7-B8AA-4A08-A580-FEAB7BACD30E</gtr:id><gtr:name>Friedrich Miescher Inst of Biomed Res</gtr:name><gtr:address><gtr:line1>Maulbeerstrasse 66</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0080451D-5137-4BF8-9900-351EEC2CDB3E"><gtr:id>0080451D-5137-4BF8-9900-351EEC2CDB3E</gtr:id><gtr:name>Molecular Biology Institute of Barcelona</gtr:name><gtr:address><gtr:line1>Molecular Biology Institute of Barcelona</gtr:line1><gtr:line2>Barcelona Science Park c/ Baldiri Reixac</gtr:line2><gtr:line3>3rd Floor</gtr:line3><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C06AF2EB-8689-4D6A-B151-4DD4BEA85138"><gtr:id>C06AF2EB-8689-4D6A-B151-4DD4BEA85138</gtr:id><gtr:name>Central European Institute of Technology</gtr:name><gtr:address><gtr:line1>Central European Institute of Technology</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/621CACAB-53EE-48C8-A5EF-69DA4FA58943"><gtr:id>621CACAB-53EE-48C8-A5EF-69DA4FA58943</gtr:id><gtr:name>Leibniz Association</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9"><gtr:id>ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9</gtr:id><gtr:name>Curie Institute Paris (Institut Curie)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/335DFBB5-7BB6-448B-AFD4-1904C4D9A808"><gtr:id>335DFBB5-7BB6-448B-AFD4-1904C4D9A808</gtr:id><gtr:name>Vlaams Instituut Biotechnologie (VIB)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0F15002C-C70C-4AD9-B432-E950F6B2FDFD"><gtr:id>0F15002C-C70C-4AD9-B432-E950F6B2FDFD</gtr:id><gtr:name>European Institute of Oncology</gtr:name><gtr:address><gtr:line1>Via Ripamonti 435</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/517D56CB-2E67-4945-B0A5-37E7F81A865A"><gtr:id>517D56CB-2E67-4945-B0A5-37E7F81A865A</gtr:id><gtr:name>Takeda Cambridge Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9A22541F-DA58-481E-8D0C-C4BCF4EA030E"><gtr:id>9A22541F-DA58-481E-8D0C-C4BCF4EA030E</gtr:id><gtr:name>EMBL - European Bioinformatics Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB10 1SD</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4CB92F40-4E51-4027-B354-8C9737DBBCAD"><gtr:id>4CB92F40-4E51-4027-B354-8C9737DBBCAD</gtr:id><gtr:name>University of Tromsoe</gtr:name><gtr:address><gtr:line1>Arctic University of Norway</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A919B771-5C0F-4AD1-B747-03D25677DC3B"><gtr:id>A919B771-5C0F-4AD1-B747-03D25677DC3B</gtr:id><gtr:name>University of Texas Southwestern Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FA04CA23-EB82-46AF-B73D-67FF08E5576E"><gtr:id>FA04CA23-EB82-46AF-B73D-67FF08E5576E</gtr:id><gtr:name>University of Ancona</gtr:name><gtr:address><gtr:line1>Faculty of Medicine</gtr:line1><gtr:postCode>I-60020</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC68D4D9-FDF1-4BA8-826F-1AF5D36C82CE"><gtr:id>FC68D4D9-FDF1-4BA8-826F-1AF5D36C82CE</gtr:id><gtr:name>Centre for Genomic Regulation (CRG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F94E0EA2-DA20-4E08-9841-2A69C2FEA91D"><gtr:id>F94E0EA2-DA20-4E08-9841-2A69C2FEA91D</gtr:id><gtr:name>Institute for Molecular Medicine Finland</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/103D3F37-4066-444D-93DA-A10CF99F10F5"><gtr:id>103D3F37-4066-444D-93DA-A10CF99F10F5</gtr:id><gtr:name>Austrian Academy of Sciences</gtr:name><gtr:address><gtr:line1>Lazarettgasse 14</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F4DC8F58-AC06-4EB1-976C-EAA0136CC12F"><gtr:id>F4DC8F58-AC06-4EB1-976C-EAA0136CC12F</gtr:id><gtr:name>Museu da Lourinh?</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39C210D7-B8AA-4A08-A580-FEAB7BACD30E"><gtr:id>39C210D7-B8AA-4A08-A580-FEAB7BACD30E</gtr:id><gtr:name>Friedrich Miescher Inst of Biomed Res</gtr:name><gtr:address><gtr:line1>Maulbeerstrasse 66</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0080451D-5137-4BF8-9900-351EEC2CDB3E"><gtr:id>0080451D-5137-4BF8-9900-351EEC2CDB3E</gtr:id><gtr:name>Molecular Biology Institute of Barcelona</gtr:name><gtr:address><gtr:line1>Molecular Biology Institute of Barcelona</gtr:line1><gtr:line2>Barcelona Science Park c/ Baldiri Reixac</gtr:line2><gtr:line3>3rd Floor</gtr:line3><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C06AF2EB-8689-4D6A-B151-4DD4BEA85138"><gtr:id>C06AF2EB-8689-4D6A-B151-4DD4BEA85138</gtr:id><gtr:name>Central European Institute of Technology</gtr:name><gtr:address><gtr:line1>Central European Institute of Technology</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/621CACAB-53EE-48C8-A5EF-69DA4FA58943"><gtr:id>621CACAB-53EE-48C8-A5EF-69DA4FA58943</gtr:id><gtr:name>Leibniz Association</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9"><gtr:id>ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9</gtr:id><gtr:name>Curie Institute Paris (Institut Curie)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/335DFBB5-7BB6-448B-AFD4-1904C4D9A808"><gtr:id>335DFBB5-7BB6-448B-AFD4-1904C4D9A808</gtr:id><gtr:name>Vlaams Instituut Biotechnologie (VIB)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0F15002C-C70C-4AD9-B432-E950F6B2FDFD"><gtr:id>0F15002C-C70C-4AD9-B432-E950F6B2FDFD</gtr:id><gtr:name>European Institute of Oncology</gtr:name><gtr:address><gtr:line1>Via Ripamonti 435</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/517D56CB-2E67-4945-B0A5-37E7F81A865A"><gtr:id>517D56CB-2E67-4945-B0A5-37E7F81A865A</gtr:id><gtr:name>Takeda Cambridge Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9A22541F-DA58-481E-8D0C-C4BCF4EA030E"><gtr:id>9A22541F-DA58-481E-8D0C-C4BCF4EA030E</gtr:id><gtr:name>EMBL - European Bioinformatics Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB10 1SD</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A8FFE8BD-0636-4C9D-A5F7-29460A47D865"><gtr:id>A8FFE8BD-0636-4C9D-A5F7-29460A47D865</gtr:id><gtr:firstName>Len</gtr:firstName><gtr:surname>Stephens</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C0A7056F-E319-488D-BC7B-EB4514B543F8"><gtr:id>C0A7056F-E319-488D-BC7B-EB4514B543F8</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>Jonathan</gtr:otherNames><gtr:surname>Cook</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8C2686BF-665F-4B6D-A835-FD1D1AA924D3"><gtr:id>8C2686BF-665F-4B6D-A835-FD1D1AA924D3</gtr:id><gtr:firstName>Michael Philip</gtr:firstName><gtr:surname>Coleman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FB%2F000C0417"><gtr:id>5340B3AB-718C-4DD8-9078-F3976A6AC002</gtr:id><gtr:title>To define the molecular mechanisms that determine cellular and organismal longevity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/B/000C0417</gtr:grantReference><gtr:abstractText>Axonal longevity. The NAD+ synthetic enzyme Nmnat2 is an essential axonal protein(38) (MC Lab) Nmnat2 must be delivered by axonal transport to sites up to a metre from the neuronal cell body for the cell to avoid entering a novel cell death pathway. This concept is the basis of our proposal that Nmnat2 is a crucial cell survival factor in neurones and we propose that this delivery, like that of other axonal transport cargoes, declines with age. Nmnat2 has a short half-life (&amp;lt;1hr). As axonal transport requires up to two days to deliver proteins to the ends of our longest axons this means processes regulating Nmnat2 transport and stability are paramount to axon survival. The consequences of losing Nmnat2 are a decline in its product, NAD+, and a rise in the substrate, NMN+. Pharmacological and genetic evidence point to a key role for NMN+ accumulation as a toxic intermediate triggering axonal degeneration. In addition to our studies on WldS, an on-going international collaboration recently led us to a new axon protective mutation (?Wld2?). Deletion of MyD88-5, an adapter protein in TLR signalling, preserves injured axons in Drosophila for the entire adult lifespan and extends axon survival in mice by tenfold (Osterloh et al, Science, revised). NAD+ as a cell survival signal. NAD+ is vital in all cell types as a redox cofactor, for Ca2+ signaling (cADPR, NAADP+), transcription and DNA repair (PARPs and sirtuins). Nampt, the rate-limiting enzyme on the NAD+ salvage pathway, promotes stress resistance and extends cellular lifespan(128). Our recent data (SC lab) suggests a novel role for Nampt in repressing apoptosis. Nampt inhibition causes cell cycle arrest, increases the expression of the pro-apoptotic proteins, including Bim, and induces cell death; these effects are rescued by nicotinic acid or NAD+ indicating that they reflect NAD+ depletion. We have shown that Bim promotes cell death arising from growth factor withdrawal with the major Bim splice variant BimEL being regulated by the ERK1/2 pathway. However, these new results potentially define a completely novel mode of regulation in which all Bim splice variants are strongly induced despite activation of ERK1/2 and PKB, two pathways that normally repress Bim. In addition, we find that Nampt inhibition results in the post-translational modification of Nampt; we speculate that this is a novel feedback regulatory event that represents the cell?s attempts to rescue NAD+ synthesis and may be relevant to declining NAD signalling with age. The role of DYRK1b in oxidative defences and cell senescence. Reactive oxygen species (ROS) elicit DNA, lipid and protein damage and ER stress that can drive apoptosis, suppress cell proliferation/growth or cause senescence. ROS damage is a common causal event in cellular and organismal models of ageing and anti-oxidant interventions extend lifespan and healthspan in model organisms. Indeed, mutations that activate the anti-oxidant transcription factor Nrf2 in Drosophila increase oxidative stress resistance and extend lifespan(129). Nrf2 drives the expression of anti-oxidant/de-toxification genes including Heme Oxygenase-1 (HMOX1). In new work we have found that the inducible protein kinase DYRK1b, which controls cell cycle progression, also promotes the expression of HMOX1 and 3 other Nrf2 target genes (SC lab). We propose that DYRK1b is a novel regulator of the Nrf2 pathway and acts to protect cells against ROS. MAPK/SAPK signalling pathways in stress responses and stress resistance. ERK1/2, JNK and p38 are activated by ER stressors and oxidants but their role in stress and stress resistance is complex and context dependent. For example, we find that ERK1/2 signalling protects against ER stress-induced death (SC lab) and it can also promote Nrf2-dependent gene expression(129); conversely, ERK1/2 activation can induce ROS production, cell cycle arrest and senescence(130) and is reduced in long-lived mice strains. Similarly, JNK can promote cell death but also increases Drosophila lifespan. Some of these conflicting studies reflect cellular context and that fact that these pathways do not act in isolation but alongside multiple concident pathways in signalling systems. We will examine this in Obj 5 (Modelling signalling networks controlling cellular longevity, SC with M. Narita, Cambridge &amp;amp; J. Saez-Rodriguez, EBI). However, we do need to resolve these paradoxes and define the role these pathways play in stress resistance and cell longevity.</gtr:abstractText><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>2019868</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Takeda Cambridge Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Axonal transport in models of premature ageing and spontaneous Alzheimer's disease</gtr:description><gtr:id>85274743-B535-4EAF-B571-C2821ED3BFC4</gtr:id><gtr:impact>None as yet - early stages.</gtr:impact><gtr:outcomeId>544a210d1fc330.13411013-1</gtr:outcomeId><gtr:partnerContribution>Provision of models and intellectual discussion</gtr:partnerContribution><gtr:piContribution>Quantification of axonal transport in models of premature ageing and spontaneous Alzheimer's disease</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca mTOR</gtr:description><gtr:id>994D2F47-FB96-4E2A-B494-757EB226B174</gtr:id><gtr:impact>The PhD student successfully completed their PhD, two papers have been published and additional work is ongoing.</gtr:impact><gtr:outcomeId>56c340cc59ad52.32361337-1</gtr:outcomeId><gtr:partnerContribution>Our partners at AstraZeneca part funded a BBSRC PhD student to do this work, provided large quantities of mTOR inhibtor as an 'in kind' contribution and performed next gen sequencing and other analyses of resistant cells to probe for mechanisms of resistance</gtr:partnerContribution><gtr:piContribution>Inhibitors of mTOR promote healthy lifespan extension in model organisms by promoting autophagy and are also undergoing evaluation as a treatment for cancer. However, complete mTOR inhibition is not compatible with life. We are interested in how the mTOR pathway is remodelled during chronic exposure to mTOR inhibitors. We have generated cells that are resistant to mTOR inhibitors and examined the mTOR pathway to identify changes that underpin resistance.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Computer Vision and Image Processing (CVIP)</gtr:department><gtr:description>Regulation of signalling through the Ras/ERK pathway by DUSPs</gtr:description><gtr:id>6CDA0ACF-3366-41AB-9B8E-E3977D1E6BE7</gtr:id><gtr:impact>Too early to assess full impacts - collaboration has only recently started.</gtr:impact><gtr:outcomeId>58c7cc3d3253b5.85855799-1</gtr:outcomeId><gtr:partnerContribution>Stephen Keyse's lab are generating unique DUSP null cell lines and mutant DUSP constructs</gtr:partnerContribution><gtr:piContribution>We are undertaking high content microscopy to assess the impact of ablating expression of dual specificity phosphatases (DUSPs) on spatiotemporal aspects of ERK signalling and resultant cell fate decisions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca ERK</gtr:description><gtr:id>2887A39E-5F94-485D-896E-33F9891267D4</gtr:id><gtr:impact>Much of this is still early stage. However, high throughput drug screening has identified several drug combinations that markedly transform the growth inhibitory effects of Selumetinib. Our analysis of new resistance models has identified several completely novel potential mechanisms which we are in the process of validating. These studies will lead to further papers in addition those publications already reported and may contribute to the testing of new drug combinations in the clinic in the future.</gtr:impact><gtr:outcomeId>546f6b7e208329.85398167-1</gtr:outcomeId><gtr:partnerContribution>AstraZeneca have performed a variety of Next Gen Seq analyses on samples provided by us to identify genetic and transcriptomic changes associated with resistance; these may be candidate resistance drivers. They are also performing xenograft studies to test specific hypotheses that emerge form our studies.
Our collaborators at the University of Bath are investigating how the magnitude of ERK1/2 signalling can impart different tumour cell responses when Selumetinib is withdrawn from resistant cells. 
In a three-way collaboration between our lab, the CRUK-CI and AstraZeneca we are peforming high throughput drug combination screens to identify drugs that combine with Selumetinib to provide superior tumour growth inhibition or tumour cell death.</gtr:partnerContribution><gtr:piContribution>We want to understand the various mechanisms by which ERK1/2 pathway-addicted tumour cells adapt and acquire resistance to the MEK1/2 inhibtor Selumetinib. We have generated a variety of human tumour cell lines with acquired resistance to the clinical candidate MEK1/2 inhibitor Selumetinib. These include cell lines in which BRAF is the driving oncogene but also those in which KRAS is the driving oncogene. We have analysed the activation state of the ERK1/2 pathway in these cells and in some cases validated the resistance mechanism. In other cases this analysis is ongoing. In some models we find that resistance is reversible upon drug withdrawal suggesting that resistant cells actually have a fitness deficit in the absence of drug. We are investigating the mechanisms that underlie this fitness deficit.
For our partner (AstraZeneca/CRUK) this may allow development of rational strategies to overcome or delay resistance and thereby provide more durable drug responses. For our own basic biological interests this should provide insights into how this key cell fate signalling pathway is regulated; this may be relevant to emerging regenerative medicine protocols.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vlaams Instituut Biotechnologie (VIB)</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>2585C437-F087-4902-AE50-42D3C3497454</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-3</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine Johns Hopkins</gtr:department><gtr:description>AH</gtr:description><gtr:id>4B4A5E56-BEDA-467D-A676-4785575828B8</gtr:id><gtr:impact>Standardisation of research methods between our groups so data is more easily compared between us. Training in peripheral neuropathy and pain models.</gtr:impact><gtr:outcomeId>5464b7f2a0e681.95479377-1</gtr:outcomeId><gtr:partnerContribution>Training in peripheral neuropathy and pain models</gtr:partnerContribution><gtr:piContribution>Exchange of knowledge on axonal transport measurements</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Curie Institute Paris (Institut Curie)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>725D324D-D9B8-43F7-ACFB-85D4C4D3386F</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-4</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Tromso</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Department of Medical Biology</gtr:department><gtr:description>p62 phosphorylation</gtr:description><gtr:id>C86E8946-5AD7-4DEF-9BB8-03F59BE4E7F4</gtr:id><gtr:impact>Too soon for any specific outputs as the collaboration has only just started. However, i have visited the University of Tromso and presented two Lectures as part of a PhD training course</gtr:impact><gtr:outcomeId>58c6c504963577.81484997-1</gtr:outcomeId><gtr:partnerContribution>Terje Johansen's lab will share reagents and expertise and perform specific experiments to define the interaction between DYRKs and p62</gtr:partnerContribution><gtr:piContribution>Sharing of data; discussion of new experimental directions; experiments
We have identified p62/SQSTM1 as a novel substrate of DYRK1B and DYRK2. We are investigating the role of this phosphorylation on p62 functions in proteostasis, stress responses and nutrient signalling</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas Southwestern Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Generation of mice with 75% reduction in NMNAT2</gtr:description><gtr:id>65F4A015-5D63-4D0E-9842-C3CAB367A81B</gtr:id><gtr:impact>We have been monitoring effects of a 75% reduction in NMNAT2 expression during aging.</gtr:impact><gtr:outcomeId>Ts8pBe1jpDp-1</gtr:outcomeId><gtr:partnerContribution>Provided gene trap mice with partial knock-down of NMNAT2 from targeted allele.</gtr:partnerContribution><gtr:piContribution>Imported gene trap mice with partial knock-down of NMNAT2 from targeted allele and crossed with our own gene trap targeted mice to be used in experiments.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>EMBL European Bioinformatics Institute (EMBL - EBI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Saez-Rodriguez ERK</gtr:description><gtr:id>F98B8BAA-747D-4F2F-9C67-8A1E918590E6</gtr:id><gtr:impact>A review article has been published and a primary research paper is in preparation and will certainly lead to additional outputs</gtr:impact><gtr:outcomeId>56c202a35ed1c2.02577968-1</gtr:outcomeId><gtr:partnerContribution>Our partners have provided bioinformatics support and training to a PhD student who was embedded in the partner group at the EBI. This included network analysis and gene set enrichment analysis. It led to some completely new insights into how ERK1/2 signalling controls cell cycle arrest/senescence</gtr:partnerContribution><gtr:piContribution>We have generated gene expression data sets from cells exhibiting different levels of ERK1/2 signalling that drive different cell fates - cell proliferation or cell cycle arrest &amp;amp; senescence.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AZ/Cosulich</gtr:description><gtr:id>16AB8EC9-8F73-4D1A-AF5C-4D53EC02514A</gtr:id><gtr:impact>Papers and models (still in development), much work is currently being written-up.</gtr:impact><gtr:outcomeId>546485a40f8d63.36861866-1</gtr:outcomeId><gtr:partnerContribution>Insights in to commercial directions and interests in this area.</gtr:partnerContribution><gtr:piContribution>We are measuring and modelling agonist and onco-mutant driven changes in PIP3 signalling and then using selective inhibitors and RNAi to understand how the PIP3 signalling network operates</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bath</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Biology and Biochemistry</gtr:department><gtr:description>Bath ERK pathway</gtr:description><gtr:id>97223513-3591-42F6-A5BF-9631E89D0FE6</gtr:id><gtr:impact>Still ongoing so major outputs still to emerge</gtr:impact><gtr:outcomeId>56c1e5a32916c7.67758633-1</gtr:outcomeId><gtr:partnerContribution>Our collaborator has access to unique reagents and protocols that will allow him to interrogate the role of the DUSPs in MEKi resistance and reversibility</gtr:partnerContribution><gtr:piContribution>We have discovered that acquired resistance to MEK inhibitors (MEKi) in tumour cells driven by BRAF amplification is completely reversible upon drug withdrawal. This has led to the realisation that ERK1/2 signalling operates within very discrete parameters/boundaries to maintain tumour cell proliferation. This information is relevant to the use and outcome of MEKi in treating cancer. We need to know the key regulators of ERK1/2 signalling during drug resistance and its reversal. We postulate that a family of genes called DUSPs may be involved in regulating the ERK1/2 under these conditions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Friedrich Miescher Institute for Biomedical Research (FMI)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>072FECBA-4475-433E-8269-F94D02166EF9</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-1</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research and Development AstraZeneca</gtr:department><gtr:description>AstraZeneca FGFR</gtr:description><gtr:id>FF597D3B-7438-4828-B6D8-B1ABAE7035A9</gtr:id><gtr:impact>Posters have been presented at three conferences. A review article and a primary research publication are currently being written.
The review article will focus on mechanisms of acquired resistance to TKIs, including FGFR
The first research paper will describe acquired resistance to FGFR inhibitors through amplification of FGFR2 in gastric cancer cells. This will include a full genomic and phosphoproteomic analysis of parental and resistant cell lines which as revealed novel cross talk between the FGFRs and the HGF/MET receptors</gtr:impact><gtr:outcomeId>546ef0260a0a54.46163036-1</gtr:outcomeId><gtr:partnerContribution>AstraZeneca have performed various Next Gen Seq protocols on samples generated by us seeking to identify genetic changes that may be responsible for AZD4547 resistance. They have provided bioinformatics support and follow up transcriptome analysis (Fluidigm, nanostrong etc). They have also provided AZD4547 and other targeted agents gratis for this collaboration</gtr:partnerContribution><gtr:piContribution>We have generated gastric cancer and breast cancer cell lines with acquired resistance to the FGFR tyrosine kinase inhibitor AZD4547. We are characterizing the molecular mechanisms of this acquired resistance, seeking to identify the how the FGFR signalling pathway is remodelled. This should provide new insights into pathway regulation that will be relevant to our partners drug discovery efforts and our own basic interests in FGF signalling and cell fate decisions</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Molecular Biology Institute of Barcelona</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>DYRK1A developmental fates</gtr:description><gtr:id>B05C0E8C-66FD-4375-A398-BF61A4BC6D7C</gtr:id><gtr:impact>A research paper was published in the journal EBioMedicine</gtr:impact><gtr:outcomeId>56c301dddadcc0.53179866-1</gtr:outcomeId><gtr:partnerContribution>To further our knowledge in this area we collaborated with Mariona Arbones in Barcelona who had generated a mouse model in which the DYRK1A gene is triplicated. These mice exhibit decreased nuclear levels of CCND1 in embryonic cortical stem(radial glia) cells, and that lengthens the G1 phase in these progenitors. These alterations promote asymmetric proliferative divisions at the expense of neurogenic divisions, producing a deficit in cortical projection neurons that persists in postnatal stages contributing to Downs like pathology</gtr:partnerContribution><gtr:piContribution>DYRK1A is triplicated in Down Syndrome and evidence suggests that it may be a primary driver of this developmental disorder. We defined cyclin D1 (CCND1) as a new substrate of the protein kinase DYRK1A.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Diane Hanger</gtr:description><gtr:id>9D15D029-1911-44F5-A161-66CA5BFCF526</gtr:id><gtr:impact>Publications:
Gilley et al (Neurobiol Aging) 2012
Rodriguez-Marting (Neurobiol Dis) 2016
Gilley et al (Neurobiol Aging) 2016</gtr:impact><gtr:outcomeId>56d8cd0a297387.56478917-1</gtr:outcomeId><gtr:partnerContribution>Analysis of axonal transport in neuronal cultures from mutant tau mice</gtr:partnerContribution><gtr:piContribution>Generation of mice with mutated forms of tau protein</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Massachusetts (UMass)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Marc Freeman</gtr:description><gtr:id>C882078D-4E52-4D0D-96A8-777621943ECD</gtr:id><gtr:impact>Publication in Science showing SARM1 is required for axon degeneration (Osterloh et al, 2012). Subsequent publication showing that removal of SARM1 can rescue axon growth in NMNAT2 null mice (Gilley et al, 2015)</gtr:impact><gtr:outcomeId>56d8ca56ca09d9.07270113-1</gtr:outcomeId><gtr:partnerContribution>Identification of dSARM as a protein required for axon degeneration in flies</gtr:partnerContribution><gtr:piContribution>Demonstration that deletion of SARM1 rescues injured axons in mice</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leibniz Association</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Leibniz-Institute for Molecular Pharmacology</gtr:department><gtr:description>Volker Haucke</gtr:description><gtr:id>B476C0DB-6D08-405A-9BBC-FC625CA24F46</gtr:id><gtr:impact>Multi-disciplinary, high content imaging, mass spectrometry, biochemisty</gtr:impact><gtr:outcomeId>58c679bc5aeaf5.69170483-1</gtr:outcomeId><gtr:partnerContribution>They have established assays of intracellualr trafficking using high content imaging technology and to measure mTOR1 distribution and roles.</gtr:partnerContribution><gtr:piContribution>Measurements of phopshoinositides and advice about assays for inostiol phosphates</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Austrian Academy of Sciences</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:department>Research Centre for Molecular Medicine (CeMM)</gtr:department><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>2B5697A8-50BF-4B75-979F-36C446FEB338</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-7</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Netherlands Cancer Institute (NKI)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>F2E3F0BB-4FCF-4358-B366-0E4F82615F6D</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-10</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Central European Institute of Technology (CEITEC)</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>A206448C-CC6B-453C-93A3-25A510DF5C8F</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-9</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK Cambridge Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CRUK CI ERK pathway</gtr:description><gtr:id>3F83EF07-C4FC-47CE-88F4-7222BEF3AA62</gtr:id><gtr:impact>Partnership/collaboration still active and ongoing. Major, outputs (publications) still to emerge</gtr:impact><gtr:outcomeId>56c1e06d8b0c12.83269370-1</gtr:outcomeId><gtr:partnerContribution>Our partners are testing some of these drug combinations in 'in vivo' mouse models - a key pre-clinical validation step</gtr:partnerContribution><gtr:piContribution>We have identified mechanisms of innate resistance to MEK inhibitors (MEKi) in human tumour cells. These mechanisms have in turn suggested drug combinations (MEKi + Xi, MEKi +Yi, etc) that should overcome innate resistance to MEK inhibitors allowing effect inhibition of the growth of tumor cells. We have tested these combinations in dozens of human cancer cell lines. The data is robust and merits further investigation, including validation in 'in vivo' mouse models</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Biotech Research and Innovation Center (BRIC)</gtr:department><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>CD98B2C3-6276-4A4E-93ED-6C90BD886FB4</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-12</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Molecular Medicine Finland</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>2463C5D5-8270-4413-8EFD-A513F15BFFA3</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-11</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helmholtz Association of German Research Centres</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>The Max Delbr?ck Center for Molecular Medicine (MDC)</gtr:department><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>D6DEED04-022A-4643-9218-B4F9482AB810</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-5</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bath</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca ERK</gtr:description><gtr:id>8E5D0B2B-B0BF-4E5C-8DA0-C54E35A11B4C</gtr:id><gtr:impact>Much of this is still early stage. However, high throughput drug screening has identified several drug combinations that markedly transform the growth inhibitory effects of Selumetinib. Our analysis of new resistance models has identified several completely novel potential mechanisms which we are in the process of validating. These studies will lead to further papers in addition those publications already reported and may contribute to the testing of new drug combinations in the clinic in the future.</gtr:impact><gtr:outcomeId>546f6b7e208329.85398167-2</gtr:outcomeId><gtr:partnerContribution>AstraZeneca have performed a variety of Next Gen Seq analyses on samples provided by us to identify genetic and transcriptomic changes associated with resistance; these may be candidate resistance drivers. They are also performing xenograft studies to test specific hypotheses that emerge form our studies.
Our collaborators at the University of Bath are investigating how the magnitude of ERK1/2 signalling can impart different tumour cell responses when Selumetinib is withdrawn from resistant cells. 
In a three-way collaboration between our lab, the CRUK-CI and AstraZeneca we are peforming high throughput drug combination screens to identify drugs that combine with Selumetinib to provide superior tumour growth inhibition or tumour cell death.</gtr:partnerContribution><gtr:piContribution>We want to understand the various mechanisms by which ERK1/2 pathway-addicted tumour cells adapt and acquire resistance to the MEK1/2 inhibtor Selumetinib. We have generated a variety of human tumour cell lines with acquired resistance to the clinical candidate MEK1/2 inhibitor Selumetinib. These include cell lines in which BRAF is the driving oncogene but also those in which KRAS is the driving oncogene. We have analysed the activation state of the ERK1/2 pathway in these cells and in some cases validated the resistance mechanism. In other cases this analysis is ongoing. In some models we find that resistance is reversible upon drug withdrawal suggesting that resistant cells actually have a fitness deficit in the absence of drug. We are investigating the mechanisms that underlie this fitness deficit.
For our partner (AstraZeneca/CRUK) this may allow development of rational strategies to overcome or delay resistance and thereby provide more durable drug responses. For our own basic biological interests this should provide insights into how this key cell fate signalling pathway is regulated; this may be relevant to emerging regenerative medicine protocols.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centre for Genomic Regulation (CRG)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>9C798B0F-86CB-4F02-B80A-3BFCB884F3AC</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-2</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Institute of Oncology (IEO)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>CF02375A-CEBC-485A-9B25-E887CEA1D561</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-8</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ancona</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Giuseppe Orsomando</gtr:description><gtr:id>C592D2F6-2796-4F57-94DA-F0E2AB07FC0F</gtr:id><gtr:impact>Publications:
Di Stefano et al (2014)
Gilley et al (2015)</gtr:impact><gtr:outcomeId>56d8cb3e1164c7.39178253-1</gtr:outcomeId><gtr:partnerContribution>Analysis of NAD related metabolites</gtr:partnerContribution><gtr:piContribution>Tissues for analysis of NAD related metabolites in conditions involving axon degeneration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK Cambridge Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca ERK</gtr:description><gtr:id>6E599BEF-8273-482D-9F80-069CB28F1F25</gtr:id><gtr:impact>Much of this is still early stage. However, high throughput drug screening has identified several drug combinations that markedly transform the growth inhibitory effects of Selumetinib. Our analysis of new resistance models has identified several completely novel potential mechanisms which we are in the process of validating. These studies will lead to further papers in addition those publications already reported and may contribute to the testing of new drug combinations in the clinic in the future.</gtr:impact><gtr:outcomeId>546f6b7e208329.85398167-3</gtr:outcomeId><gtr:partnerContribution>AstraZeneca have performed a variety of Next Gen Seq analyses on samples provided by us to identify genetic and transcriptomic changes associated with resistance; these may be candidate resistance drivers. They are also performing xenograft studies to test specific hypotheses that emerge form our studies.
Our collaborators at the University of Bath are investigating how the magnitude of ERK1/2 signalling can impart different tumour cell responses when Selumetinib is withdrawn from resistant cells. 
In a three-way collaboration between our lab, the CRUK-CI and AstraZeneca we are peforming high throughput drug combination screens to identify drugs that combine with Selumetinib to provide superior tumour growth inhibition or tumour cell death.</gtr:partnerContribution><gtr:piContribution>We want to understand the various mechanisms by which ERK1/2 pathway-addicted tumour cells adapt and acquire resistance to the MEK1/2 inhibtor Selumetinib. We have generated a variety of human tumour cell lines with acquired resistance to the clinical candidate MEK1/2 inhibitor Selumetinib. These include cell lines in which BRAF is the driving oncogene but also those in which KRAS is the driving oncogene. We have analysed the activation state of the ERK1/2 pathway in these cells and in some cases validated the resistance mechanism. In other cases this analysis is ongoing. In some models we find that resistance is reversible upon drug withdrawal suggesting that resistant cells actually have a fitness deficit in the absence of drug. We are investigating the mechanisms that underlie this fitness deficit.
For our partner (AstraZeneca/CRUK) this may allow development of rational strategies to overcome or delay resistance and thereby provide more durable drug responses. For our own basic biological interests this should provide insights into how this key cell fate signalling pathway is regulated; this may be relevant to emerging regenerative medicine protocols.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Museu da Lourinh?</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:department>Gulbenkian Institute of Science</gtr:department><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>90C4790E-FE66-4064-9E14-479AD55393CB</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-6</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Visits by Teachers</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>86E741AB-F3FC-4586-BEE4-C16469D5BB12</gtr:id><gtr:impact>I hosted two 6th form Biology teachers (one PhD trained, the other MSc trained) who were visiting my Institution during Half Term to update their knowledge as part of their CPD</gtr:impact><gtr:outcomeId>56c1e8c3788c99.07519338</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>31557B65-892B-4A8E-ADDC-E77A0DE06D1C</gtr:id><gtr:impact>Exhibit at Cambridge Science Festival was attended by all age groups with extensive interaction and discussion</gtr:impact><gtr:outcomeId>56d8ce6350d1e8.87454856</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Bedford Mental Health Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4DEC7919-6801-47B4-ABE3-0156F6255586</gtr:id><gtr:impact>Talk was well recieved and sparked discussion

Discussion of scientific methods to a largely medical audience</gtr:impact><gtr:outcomeId>5626050e79c744.13083633</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public engagement ageing meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>49B8401B-ED92-4BFF-98E6-4DE3296BC686</gtr:id><gtr:impact>A meeting held at Cambridge Guildhall with brief presentations from a panel of mixed scientific backgrounds followed by Q&amp;amp;A and group discussions; also practical demonstrations of how reaction times, hearing, etc changes with age</gtr:impact><gtr:outcomeId>56d8cee11d7279.62768293</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Caf? Scientifique presentation (Cambridge 2012)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CF0FFD57-EDF3-4BCB-B859-BE9F39E19BC5</gtr:id><gtr:impact>Many people attended talk entitled &amp;quot;keeping your nerves&amp;quot;.

Positive feedback about research</gtr:impact><gtr:outcomeId>C4oUj6DWUUF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>63F85B2B-E71D-4F6B-9BC0-3228B3FB1C27</gtr:id><gtr:impact>Students visited the lab and undertook small lab-based proejcts supervised by students/post-docs and myself. I explained the research that we do and discussed ethical issues such as the use of animals in research.
This precipitated excellent discussion and dialogue.

We received excellent feedback from the schools involved and requests for further outreach activities</gtr:impact><gtr:outcomeId>546f1146bc7243.35670753</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits: 3 presentations to secondary school/6th formers</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2EA04451-FC67-453A-AEDD-279BF0771BC3</gtr:id><gtr:impact>Lay science presentation about the nervous system in general and axon survival specifically. Also dealt with issues including how basic science leads to unpredictable but useful outcomes (GFP, monoclonal antibodies, etc) and careers advice

Very positive feedback. Too early to know effect on exam results.</gtr:impact><gtr:outcomeId>r1m1S6DiWpp</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio/podcast interview (BBC Radio Cambridgeshire, 2012)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AC41F26A-F2FE-44B7-B540-C24D9C0037A5</gtr:id><gtr:impact>Not quantifiable

Positive feedback from people who had heard the broadcast</gtr:impact><gtr:outcomeId>TLs3DzZrCAY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public discussion (Cambridge, UK 2012)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8728AC37-FD8E-424D-ABB9-E8A18A7842CF</gtr:id><gtr:impact>Informed Q&amp;amp;A session with a panel of experts and members of the public about aging research

Useful feedback</gtr:impact><gtr:outcomeId>FtwcaauEf96</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited lecturer to international meetings (average 2-3 per year)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B611C471-25B9-4AB5-949D-150805AAC3A5</gtr:id><gtr:impact>promoted discussions, collaborations

scientific collaborations, joint grants and publications</gtr:impact><gtr:outcomeId>546215ce564be0.43637759</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>177A7426-BDE7-4194-9AF1-D53A17C44B1B</gtr:id><gtr:impact>Lots of interest in our axon transport exhibit

Exhibit has been used at multiple events since, including pint of science and school visits</gtr:impact><gtr:outcomeId>56260e3ad68743.19316982</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public feedback exercise</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6B517E84-1686-4675-84D4-3170FF6C17DE</gtr:id><gtr:impact>The Signalling Department, in parallel with other BI departments, presented our research to a professionally selected sample of the UK public with the interntion of gaining public feedback on our institute and research.</gtr:impact><gtr:outcomeId>56b883af3884f0.51484512</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Understanding Animal Research Institute Lay Presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BC3329CD-C85F-4DF7-BFA7-F54CBBA63C58</gtr:id><gtr:impact>Much discussion afterwards. Positive feedback from non-scientific staff at the institute

Invited to talk at Hills Road Sixth Form College</gtr:impact><gtr:outcomeId>562601719bf739.68567294</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Development strategy council</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1001C4EC-7CCD-440E-B3D0-481CC2CFD346</gtr:id><gtr:impact>Part of an international panel of experts convened by the Greek Economic Ministry to help develop Biotech industries in Greece</gtr:impact><gtr:outcomeId>58c6b6465aa376.22733525</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Hills Road 6th Form College</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>89A93C41-D1A3-4198-A39A-C51624F5315C</gtr:id><gtr:impact>Lots of discussion afterwards about Alzheimer's Disease and the use of animals in research. Very positive feedback and students followed up with further emailed questions.

A number of students who were doing extended research projects on Alzheimer's Disease asked further questions by email.</gtr:impact><gtr:outcomeId>562600d6299238.13196369</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>In conversation with the Babraham Institute - part of Cambridge Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9C58F1AC-C3DF-48ED-8E5C-E1D3C5BCFAD6</gtr:id><gtr:impact>1:1 dialogue with general public (open invitation but registration required for numbers). 
Evening reception in which we explain our science and answer questions
Part of a programme of events for the annual Cambridge Science Festival</gtr:impact><gtr:outcomeId>58c6c8ec91ae08.38724308</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentations to sixth formers</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>25C2F59E-1F68-4F43-AC0D-9FF4A0D8A3AF</gtr:id><gtr:impact>Approx 45 sixth formers attended a talk on axon degeneration and discussed the topic afterwards</gtr:impact><gtr:outcomeId>56d8cdfa9f3ae2.56686628</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>327000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Response mode project grant</gtr:description><gtr:end>2020-05-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/P007015/1</gtr:fundingRef><gtr:id>4B4CDFFF-F710-4EAF-B1CA-9FE192173E10</gtr:id><gtr:outcomeId>58c6c6eaba2137.38577570</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>CASE studentship awards from Takeda (Cambridge) Ltd</gtr:description><gtr:firstYearOfImpact>2014</gtr:firstYearOfImpact><gtr:id>11A19918-9CF0-4ED7-B7A5-D80217A08426</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56d8d3c8338340.79372404</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>FGFRi resistant cell lines and information derived from them that may define druggable mechanisms of acquired resistance</gtr:description><gtr:grantRef>BBS/E/B/000C0417</gtr:grantRef><gtr:id>DA5E5504-A931-41CB-BBA3-1C991BF1A163</gtr:id><gtr:impact>These are still currently in development in collaboration with our partners</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>546ef2f42952c6.07480489</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Identification of genes/enzymes driving resistance to FGFR inhibtors</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Reducing levels of the metabolite NMN in axons can prevent axon degeneration</gtr:description><gtr:grantRef>BBS/E/B/000C0417</gtr:grantRef><gtr:id>BA474713-2AFA-45D6-BDE7-73CB0888E417</gtr:id><gtr:impact>Application for Wellcome Trust Seeding Drug Discovery award</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56d8d20e572768.39878494</gtr:outcomeId><gtr:patentId>WO2011135332 A4</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>NMN Modulators for the treatment of neurodegenerative disorders</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>MEKi resistant cell lines and information derived from them that may define druggable mechanisms of acquired resistance</gtr:description><gtr:grantRef>BBS/E/B/000C0417</gtr:grantRef><gtr:id>4AF8E008-AB4E-488E-AE32-20C2BB362093</gtr:id><gtr:impact>Too early stage at the moment. This project will identify genes/enzymes driving resistance to MEK1/2 inhibitors; these may prove to be druggable and so may lead to new drug development programmes and potentially to new treatment options in the future</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>548ea8e2b31e47.14847419</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Identification of genes/enzymes driving resistance to MEK1/2 inhibtors</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>In collaboration with MISSION Therapeutics the PhD student has screened and identified DUBs that determine whether ERK pathway or mTOR inhibition leads ot cell death or not. These might be potential drug targets</gtr:description><gtr:grantRef>BBS/E/B/000C0417</gtr:grantRef><gtr:id>1E23B5D1-44E0-4E9A-8733-A47EE9902101</gtr:id><gtr:impact>Too early for direct impacts. Further validation and characterisation required</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58c7c6252a39a6.70431759</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Identification of Deubiquitylating enzymes that arbitrate cell death in response ot ERK pathway or mTOR inhibition</gtr:title><gtr:yearProtectionGranted>2017</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>Cell cycle progression is intimately linked to phospholipid metabolism and biosynthesis.
Axonal transport declines during ages in two phases.
SARM1 is required for axon degeneration
NMNAT2 is required for axon growth in vivo and NMNAT2 deficient axons can be rescued by WLDS or removal of SARM1
NMN accumulates after axon injury and promotes axon degeneration.
SARM1 is required for axon degeneration downstream of loss of NMNAT2
Deletion of SARM1 rescues NMNAT2 deficient axons for the entire lifespan, unlike WLDS which rescues only for several months
NMNAT2 depletion makes axonal more vulnerable to a range of stresses including ageing
Disruption of NAD+ synthesis activates a protein kinase called AMPK to inhibit mTOR signalling, thereby shutting down mRNA translation and driving the loss of key cell survival proteins. Loss of NAD+ also increases the expression of key pro-apoptotic proteins; together these events predispose cells to undergo programmed cell death
We have identified the protein kinases DYRK1A and DYRK1B as novel regulators of the G1 cell cycle transition through their ability to phosphorylate cyclin D1. In the case of DYRK1A, our collaborators in Barcelona have shown that this may contribute to the development of Down's syndrome using a novel mouse model with triplicated DYRK1A.
In collaboration with colleagues in the Lymphocyte Signalling and Development ISP we have demonstrated that the mRNA binding proteins ZFP36L1 and ZFP36L2 are key regulators of the G1-S cell cycle progression and quiescence.
We have found that ER stress (a hallmark of ageing) causes inactivation of the ERK1/2 signalling pathway. If we prevent this inactivation of ERK1/2 we can protect cells from ER stress induced apoptosis indicating that ERK1/2 signalling arbitrates survival/death decisions.</gtr:description><gtr:exploitationPathways>Understanding that manipulating phospholipid metabolism can affect cell survival.
Rescue of axons during ageing and in neurodegenerative disease.
Our results are of broad relevance to the pharmaceutical sector where AMPK/mTOR, DYRK and ERK1/2 signalling is of interest in range of diseases of old age including cancer, neurodegeneration and metabolic disease.</gtr:exploitationPathways><gtr:id>410936BB-121D-466D-A38B-4C27227311D7</gtr:id><gtr:outcomeId>56d72aebe2aa49.65331213</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Scientific Advisory Board of Cancer Research Technology Discovery Lab</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A8E9D22B-6C5D-471D-BB57-487D2833C8B3</gtr:id><gtr:outcomeId>58c7ba68ae98d8.97108955</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>In collaboration with MISSION Therapeutics we have undertaken an RNAi screen with human deubiquitylating enzymes (DUBs) to identify those DUBs that confer protection against ERK pathway, mTOR inhibition or PERK inhibition
Datat is currently being analysed before candidates are selected for further characterisation</gtr:description><gtr:id>2725846D-44AA-4076-B58F-F87EB29FC505</gtr:id><gtr:impact>Too early for impacts
This data will be made available to the community in the future</gtr:impact><gtr:outcomeId>58c7ab157de279.78009312</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>DUB RNAi screen</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>RNA-seq data set derived from HEK293 cells which exhibit Tet-regulated DYRK2 expression
Reports genome wide changes in abundance and splicing patterns in response to DYRK2 expression</gtr:description><gtr:id>A05AA469-9ECE-4AE0-A39A-B79EC05758E5</gtr:id><gtr:impact>Too soon for impacts. Data currently being analysed</gtr:impact><gtr:outcomeId>58c7a5eaba2e09.54170308</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DYRK2 Transcriptome gene data set</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Human Illumina bead array descricing genome-wide changes in mRNA expression in parental and MEKi resistant cells</gtr:description><gtr:id>FF58B41A-CE78-4375-AF39-380A8DC2D1DF</gtr:id><gtr:impact>One primary research paper and review articles. Demonstration of mechanism by which tumour cells acquire resistance to MEK inhibitors</gtr:impact><gtr:outcomeId>56c34f401f6057.07459789</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MEKi resistance gene set</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>RNA-seq data set derived from HEK293 cells which exhibit Tet-regulated DYRK1B expression
Reports genome wide changes in abundance and splicing patterns in response to DYRK1B expression</gtr:description><gtr:id>B6509921-49D7-44FF-8F06-CE51D7F3B001</gtr:id><gtr:impact>Too soon for impacts. Data currently being analsyed</gtr:impact><gtr:outcomeId>58c7a59800f722.99170452</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DYRK1B transcriptome gene data set</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Human Illumina bead array describing changes in transcriptome associated with ERK-driven cell cycle arrest/senescence</gtr:description><gtr:id>4FF54F5D-6F3C-48C0-BC1B-B6DFEB2FBB71</gtr:id><gtr:impact>New insights into ERK signalling associated with cell cycle arrest and senescence
Identification of new links between ERK signalling the cell cycle
Identification of ERK target genes</gtr:impact><gtr:outcomeId>58c6cd30235b25.97893267</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ERK pathway cell cycle arrest/senescence gene data set</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Human Illumina bead array data for comparison of differences in gene expression between parental and FGFRi-resistant KMS11 cells. Referecne paper
Chell et al (2013) Oncogene. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance</gtr:description><gtr:id>4E44FEF0-7218-4FA4-BB93-BCC533E10039</gtr:id><gtr:impact>Data contributed to a primary research paper and helped to define the first reported mechanism of acquired resistance to FGFR inhibitors</gtr:impact><gtr:outcomeId>56c34d65e9d019.02593465</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Illumina mRNA dataset FGFRi</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-1222/</gtr:url></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>HEK293 cells lines engineered to exhibit Tet-inducible expression of the DYRK1B protein kinase</gtr:description><gtr:id>7F85F3F3-C289-415B-916A-913A0C461C23</gtr:id><gtr:impact>New knowledge of the biological function of the DYRK1B protein kinase, including new substrates.
New research papers
New collaborations</gtr:impact><gtr:outcomeId>56e133c4483a49.87246099</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Inducible DYRK1B cells</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated HCT116 cell liens in which we have deleted the RNA binding proteins ZFP36L1 or ZFP36L2 - singly or in combination (DKO) using CRISPR/Cas9 gene editing.</gtr:description><gtr:id>EBC1A727-6A94-4644-80B0-0D9D1C5DB89D</gtr:id><gtr:impact>ZFP36L1 KO cells featured in our 2016 manuscript - Galloway et al Science
Further impacts will arise as we undertake further characterisation of these cell lines
These will be made available to the community in the future</gtr:impact><gtr:outcomeId>58c7a6fb607720.07920877</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ZFP36 KO cell llines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>HEK293 cells lines engineered to exhibit Tet-inducible expression of the DYRK2 protein kinase</gtr:description><gtr:id>511219A9-7E95-4658-B40E-8004E3A54DFE</gtr:id><gtr:impact>New knowledge of DYRK2
Identification of new substrates of DYRK2</gtr:impact><gtr:outcomeId>58c6cb51503056.35567971</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Inducible DYRK2 cell line</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated gastric, breast and myeloma cells with acquired resistance to AZD4547, an FGFR inhibitor undergoing clinical evaluation, and a second closely related molecule.
We have now performed genome-wide gene expression, exome sequencing and phospho-proteomics analysis on parental and resistant cells.</gtr:description><gtr:id>AD6EB4FE-6140-4255-99EA-520E0EA33BEE</gtr:id><gtr:impact>We have generated a host of new information on genetic, transcriptomic and biochemical changes associated with acquired resistance to these drugs. We are currently mining this information and testing specific gene products as candidate drivers of resistance. This information is being shared with project partners.
This data will be made freely available as each study is published allowing other researchers to access and benefit from our datasets</gtr:impact><gtr:outcomeId>546ef1df2dc760.07420463</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>FGFRi resistant cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated human cell lines (cancer cells and primary human fibroblasts) with adaptive resistance to the mTOR inhibitors rapamycin and AZD8055</gtr:description><gtr:id>8059B891-2A96-4177-AA1B-329158525EC1</gtr:id><gtr:impact>Two papers have been published and this has provided insight in to likely mechanisms by which cancer cells may adapt and acquire resistance to mTOR inhibitors</gtr:impact><gtr:outcomeId>56c34733c8e629.16611224</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>mTORi resistant cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated a novel mutant mouse line from a EUCOMM gene trap clone targeting the Nmnat2 gene. The gene trap is conditional such that it can be inactivated and then reactivated to assess the effects of Nmnat2 depletion in mature mice.</gtr:description><gtr:id>DF4C19D9-1D8B-49B6-B056-7880629CB3BA</gtr:id><gtr:impact>Initial experiments indicate that knock-down of Nmnat2 expression from the trapped allele is substantial or complete. We have bred heterozygotes with an active gene trap, and have found that homozygotes die just before, or at birth. We have shown that this reflects an axonal growth defect and we have rescued this defect with the WldS gene. We find evidence for compensatory changes that allow heterozygotes to develop normally and survive. The heterozygote mice are being aged to study whether Nmnat2 loss contributes to age-related axon loss.</gtr:impact><gtr:outcomeId>dzAxaQbYttU</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Nmnat2 gene trap mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated HCT116 cell lines lacking one or other or both (DKO) of the critical NFkB activating protein kinases IKKalpha or IKKbeta using CRISPR/Cas9 gene targeting.</gtr:description><gtr:id>EF8936FC-4BFC-4374-A4F8-32ED535C699E</gtr:id><gtr:impact>Too early for impacts; cells still being charatcerised.
These will be made available to the community in the future</gtr:impact><gtr:outcomeId>58c7a9eca0fa27.74525116</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>IKKalpha and IKKbeta KO cell lines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have used CRISPR/Cas9 gene editing to generate COLO205 cell line clones lacking the CDK inhibitor p57KIP2 encoded by CDKN1C</gtr:description><gtr:id>11E22770-30B9-43A5-8E46-907475E0D3D0</gtr:id><gtr:impact>We have used these celsl to demonstrate the role of p57KIP2 in ERK-driven cell cycle arrest. This will form part of a future manuscript.
Additional impacts will emerge as we undertake further analysis
These will be made available to the community in the future</gtr:impact><gtr:outcomeId>58c7a7a5489ed9.29149329</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CDKN1C/p57KIP2 KO cell lines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated a panel of colorectal cancer cell lines (BRAFmut or KRASmut) with acquired resistance to the MEK inhibitor Selumetinib.</gtr:description><gtr:id>6D399F36-7FA5-4544-89C1-8AADD36C510C</gtr:id><gtr:impact>We have generated a host of new information on genetic, transcriptomic and biochemical changes associated with acquired resistance to these drugs. We are currently mining this information and testing specific gene products as candidate drivers of resistance. This information is being shared with project partners</gtr:impact><gtr:outcomeId>548ea7109d2299.72714102</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MEKi resistant tumour cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9C3FE6CC-4D2C-4A75-ABDC-8D4249E67384</gtr:id><gtr:title>Subcellular localization determines the stability and axon protective capacity of axon survival factor Nmnat2.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d58a9a5ad825cb71ef07d1ae5f07ccce"><gtr:id>d58a9a5ad825cb71ef07d1ae5f07ccce</gtr:id><gtr:otherNames>Milde S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>54648c11c6dce7.82782941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C854F032-314D-4654-9B0B-6B887C93D24B</gtr:id><gtr:title>Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent Probe.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/909e68dd43861b9c25e710cddcbfce2e"><gtr:id>909e68dd43861b9c25e710cddcbfce2e</gtr:id><gtr:otherNames>Sipthorp J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>5aa6aa1d7a7997.74707885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CA2A69D-2989-49A7-A71D-3EA65EE8827D</gtr:id><gtr:title>Molecular definitions of autophagy and related processes.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f446e86d6836d8e6a5da49dfe563b87"><gtr:id>8f446e86d6836d8e6a5da49dfe563b87</gtr:id><gtr:otherNames>Galluzzi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>5aa65b9f146ba8.88739901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9245C5AE-3FBD-46EF-962E-2B8C51195F94</gtr:id><gtr:title>Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c74644e7b4455a2471cfce5f4a2f7eb"><gtr:id>0c74644e7b4455a2471cfce5f4a2f7eb</gtr:id><gtr:otherNames>Cope CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>54648d689a5e11.39412044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47560432-D6C3-405F-BE8D-2DBBACB1ADAF</gtr:id><gtr:title>Review: Axon pathology in age-related neurodegenerative disorders.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e8e5a977709d524d14a969a1a1ce957"><gtr:id>5e8e5a977709d524d14a969a1a1ce957</gtr:id><gtr:otherNames>Adalbert R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>56d8c47c4a8c43.70348506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AE6530B-DA07-4684-A213-2F3CFE4F7CE7</gtr:id><gtr:title>Regulation of MEK/ERK pathway output by subcellular localization of B-Raf.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b22885eaba3fe954853a36984871f82c"><gtr:id>b22885eaba3fe954853a36984871f82c</gtr:id><gtr:otherNames>Andreadi C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>546f5108e45659.19931848</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7F37ABB-BE51-4CA0-A00F-954BE49C8F61</gtr:id><gtr:title>Axonal transport declines with age in two distinct phases separated by a period of relative stability.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d58a9a5ad825cb71ef07d1ae5f07ccce"><gtr:id>d58a9a5ad825cb71ef07d1ae5f07ccce</gtr:id><gtr:otherNames>Milde S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d8c5b667c050.90794940</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C0D7CFC-B78E-4602-9673-963BCE0FB7A9</gtr:id><gtr:title>Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d9a51fb590ce42722d2925380aa98f5"><gtr:id>3d9a51fb590ce42722d2925380aa98f5</gtr:id><gtr:otherNames>Cook SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>5a2faee6dec678.71936775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBD077D3-1F1A-4D3E-9E15-27039D20ED0D</gtr:id><gtr:title>The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G1 cell-cycle arrest and not a direct effect on BIK protein stability.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04fa2c0e92ddbd2d617abc0a02bdeb94"><gtr:id>04fa2c0e92ddbd2d617abc0a02bdeb94</gtr:id><gtr:otherNames>Sale MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>54648d682cd734.46403713</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ECB63C2-B3EF-428B-8BAC-E02A6A3660B3</gtr:id><gtr:title>Epigenetic memory of the first cell fate decision prevents complete ES cell reprogramming into trophoblast.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfc36c842c43f3126416dda699d912d5"><gtr:id>cfc36c842c43f3126416dda699d912d5</gtr:id><gtr:otherNames>Cambuli F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>548ea55ae82737.45621464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1D10498-9C82-4001-BF0D-938475FBA96E</gtr:id><gtr:title>The phosphoinositide 3-kinase isoform PI3K? regulates osteoclast-mediated bone resorption in humans and mice.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9dbc474049ae4add6a52c620827b2ca"><gtr:id>a9dbc474049ae4add6a52c620827b2ca</gtr:id><gtr:otherNames>Gyori D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>5463716073cfa3.35502106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEBA82C5-EDDB-40E4-A981-AD528CC18DAF</gtr:id><gtr:title>Understanding Axonal Transport And Implications For Neurodegenerative Diseases: A Dual-Colour Microscopy Study In Living Neurons</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22fd86e1d54d58858db14f6abefcb981"><gtr:id>22fd86e1d54d58858db14f6abefcb981</gtr:id><gtr:otherNames>Christy Oi Ying Hung</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58b051da8d1960.48984818</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2369E7A-A580-402B-8CE8-C36CBC4D7F1F</gtr:id><gtr:title>Using lipidomics analysis to determine signalling and metabolic changes in cells.</gtr:title><gtr:parentPublicationTitle>Current opinion in biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9800dd3dc3368924333a50a36d3f896a"><gtr:id>9800dd3dc3368924333a50a36d3f896a</gtr:id><gtr:otherNames>Nguyen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0958-1669</gtr:issn><gtr:outcomeId>58a1abdc828883.45085119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5251443C-BE68-4B2A-8B56-262D5B8F81FE</gtr:id><gtr:title>A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3? to phosphorylate cyclin D1 at Thr(286), not Thr(288).</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea54ab82aba2213e8c92cae7376f0076"><gtr:id>ea54ab82aba2213e8c92cae7376f0076</gtr:id><gtr:otherNames>Ashford AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>54648d68be3ea8.72394017</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D974A05E-37E7-4562-9BA6-CF7955E4D16B</gtr:id><gtr:title>Perturbations of PIP3 signalling trigger a global remodelling of mRNA landscape and reveal a transcriptional feedback loop.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51585f72da0559dba579b0473aa0f917"><gtr:id>51585f72da0559dba579b0473aa0f917</gtr:id><gtr:otherNames>Kiselev VY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>56b0cdd91ead15.09218035</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C925393A-7F74-46F7-965F-E53B94DF3FE5</gtr:id><gtr:title>ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f30e607a2f14029f1decfbd34338e74a"><gtr:id>f30e607a2f14029f1decfbd34338e74a</gtr:id><gtr:otherNames>Kidger AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>5aa6aa1d319ab8.84660122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67C7D349-154C-4690-ACA6-CBCFF8524351</gtr:id><gtr:title>Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1a1df1b82f1b53aa55429bb05ea222b"><gtr:id>a1a1df1b82f1b53aa55429bb05ea222b</gtr:id><gtr:otherNames>Clark DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>57bc2423395561.83359455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC120CDC-458D-4DA8-8DA2-3A425785E81C</gtr:id><gtr:title>A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4567fd8ee15a273550144bd1ab1c52af"><gtr:id>4567fd8ee15a273550144bd1ab1c52af</gtr:id><gtr:otherNames>Di Stefano M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>54648c110586f2.67676294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20D1880B-B087-48E9-B14E-65C810E628C0</gtr:id><gtr:title>MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4e408dbf8f9d90183ed694ebfa36a55"><gtr:id>c4e408dbf8f9d90183ed694ebfa36a55</gtr:id><gtr:otherNames>Caunt CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>56459b1d5161f3.02737176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12F95475-236E-4C0B-B15E-797D155F41B4</gtr:id><gtr:title>Identification of palmitoyltransferase and thioesterase enzymes that control the subcellular localization of axon survival factor nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2).</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d58a9a5ad825cb71ef07d1ae5f07ccce"><gtr:id>d58a9a5ad825cb71ef07d1ae5f07ccce</gtr:id><gtr:otherNames>Milde S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>54648c112e3367.45455982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92EC9688-5652-474A-BFC5-39541CDB89EE</gtr:id><gtr:title>CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78262698bd2c49ee0e8ffdae19911d01"><gtr:id>78262698bd2c49ee0e8ffdae19911d01</gtr:id><gtr:otherNames>Gilley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>546f51089a20b5.37391864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1720FC72-02C7-48C1-B917-4CC53F69319A</gtr:id><gtr:title>DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome.</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8db1286f26f7e679a9de8bd39480d50"><gtr:id>b8db1286f26f7e679a9de8bd39480d50</gtr:id><gtr:otherNames>Najas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>56459b1d7f99e0.04789920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50D26A56-5AB8-446A-A232-459105E53694</gtr:id><gtr:title>De-RSKing ERK - regulation of ERK1/2-RSK dissociation by phosphorylation within a disordered motif.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f30e607a2f14029f1decfbd34338e74a"><gtr:id>f30e607a2f14029f1decfbd34338e74a</gtr:id><gtr:otherNames>Kidger AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>5aa6aa1d0f3752.82694685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>636AC1D2-8A40-4430-B578-8780C12EE959</gtr:id><gtr:title>Intra-axonal calcium changes after axotomy in wild-type and slow Wallerian degeneration axons.</gtr:title><gtr:parentPublicationTitle>Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e8e5a977709d524d14a969a1a1ce957"><gtr:id>5e8e5a977709d524d14a969a1a1ce957</gtr:id><gtr:otherNames>Adalbert R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0306-4522</gtr:issn><gtr:outcomeId>56d8c47c76dc19.80517411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8562BEF8-7658-456D-9A55-409FFEC391BC</gtr:id><gtr:title>Calcium phosphate particles stimulate interleukin-1? release from human vascular smooth muscle cells: A role for spleen tyrosine kinase and exosome release.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and cellular cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c8b26039e6a7e8976a2ea75be453fa6"><gtr:id>6c8b26039e6a7e8976a2ea75be453fa6</gtr:id><gtr:otherNames>Dautova Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-2828</gtr:issn><gtr:outcomeId>5aa6aa1cd12b57.67860880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAFC0AC4-8D2C-468C-A0DA-CEC56CA190AA</gtr:id><gtr:title>RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04c8990ce80a28677e7463d99b5ba4fb"><gtr:id>04c8990ce80a28677e7463d99b5ba4fb</gtr:id><gtr:otherNames>Galloway A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>58c6c0eab496b7.86765908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDB36D87-8389-45BA-9F73-1F1EEF58A9AC</gtr:id><gtr:title>Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34ccfb591443e7db7227530de21d9b2a"><gtr:id>34ccfb591443e7db7227530de21d9b2a</gtr:id><gtr:otherNames>Rodr?guez-Mart?n T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>56d8c5b5b2aad8.38942695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F4890E9-D9FF-472D-AE61-98F8EF50F4F0</gtr:id><gtr:title>FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dec6cf848835dc1cbdbd7ef7bee2cd34"><gtr:id>dec6cf848835dc1cbdbd7ef7bee2cd34</gtr:id><gtr:otherNames>Ficz G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn><gtr:outcomeId>54648d691b4d90.06337524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>797E529D-D2C4-4999-93A0-C7C153C2D6F5</gtr:id><gtr:title>Short-term diabetic hyperglycemia suppresses celiac ganglia neurotransmission, thereby impairing sympathetically mediated glucagon responses.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3fe1925700095217fdd31a987b6ba4e"><gtr:id>b3fe1925700095217fdd31a987b6ba4e</gtr:id><gtr:otherNames>Mundinger TO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0193-1849</gtr:issn><gtr:outcomeId>56d8c5b61b1f41.55202783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DE2F57C-057A-4171-A9D3-C3A16893FED0</gtr:id><gtr:title>Stimulating translational research: several European life science institutions put their heads together.</gtr:title><gtr:parentPublicationTitle>Trends in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8479b792c385ceeaa8f7e0f8f5b7482"><gtr:id>a8479b792c385ceeaa8f7e0f8f5b7482</gtr:id><gtr:otherNames>Bentires-Alj M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-4914</gtr:issn><gtr:outcomeId>56459b1d19cd42.75752579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DE14E7B-DE10-4409-BF9B-5904F55AB6B9</gtr:id><gtr:title>Wallerian degeneration: an emerging axon death pathway linking injury and disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48c8fdc8b340458d25f8cd9c1f056b93"><gtr:id>48c8fdc8b340458d25f8cd9c1f056b93</gtr:id><gtr:otherNames>Conforti L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>54648c1178e239.22234321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A092779-CD48-4793-8A96-AEF111D52F8A</gtr:id><gtr:title>ERK1/2 signalling protects against apoptosis following endoplasmic reticulum stress but cannot provide long-term protection against BAX/BAK-independent cell death.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6729b387bf4e554c2fee167548dc24df"><gtr:id>6729b387bf4e554c2fee167548dc24df</gtr:id><gtr:otherNames>Darling NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a2fcd7910fd29.87826548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03C5D93E-3B3F-43CE-9CA7-C289442C2979</gtr:id><gtr:title>KIF1A mediates axonal transport of BACE1 and identification of independently moving cargoes in living SCG neurons.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d297cf9179b2ed37da7979221ff04298"><gtr:id>d297cf9179b2ed37da7979221ff04298</gtr:id><gtr:otherNames>Hung CO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>57bc247cc880d3.73094023</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>333A4F7B-1A19-4A44-8C9E-8ED72D947387</gtr:id><gtr:title>Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/335ea1a5172fc6d0d647e3c40642d987"><gtr:id>335ea1a5172fc6d0d647e3c40642d987</gtr:id><gtr:otherNames>Juvin V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5463715fc2e9c6.13249742</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B2E18F9-7653-4F73-9E49-BB82EC325BA6</gtr:id><gtr:title>Cell cycle progression is an essential regulatory component of phospholipid metabolism and membrane homeostasis.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2bb605d81e996783f52e2afef2eb0f8"><gtr:id>c2bb605d81e996783f52e2afef2eb0f8</gtr:id><gtr:otherNames>Sanchez-Alvarez M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>56af82db1bc4e7.33593651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C856CCB8-DD9D-4566-AC2F-6062A1B6F78F</gtr:id><gtr:title>Adaptation to chronic mTOR inhibition in cancer and in aging.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78262698bd2c49ee0e8ffdae19911d01"><gtr:id>78262698bd2c49ee0e8ffdae19911d01</gtr:id><gtr:otherNames>Gilley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>54648d68ea6744.51382837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEC58444-C07C-40D3-93F3-EAAFDA9AEBB3</gtr:id><gtr:title>Rescue of peripheral and CNS axon defects in mice lacking NMNAT2.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e775577e058c629edaa52170e133fdc"><gtr:id>6e775577e058c629edaa52170e133fdc</gtr:id><gtr:otherNames>Gilley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>56d8c5b6d99ab6.85520599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>069DECE9-2F40-47E5-99CC-956E5DBBF7BD</gtr:id><gtr:title>Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.</gtr:title><gtr:parentPublicationTitle>Cellular and molecular life sciences : CMLS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea54ab82aba2213e8c92cae7376f0076"><gtr:id>ea54ab82aba2213e8c92cae7376f0076</gtr:id><gtr:otherNames>Ashford AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1420-682X</gtr:issn><gtr:outcomeId>56459b1cd0db04.02657150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB2C2ACC-F968-462C-B55B-567BC0F6D8DE</gtr:id><gtr:title>The challenges of axon survival: introduction to the special issue on axonal degeneration.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c146feeef9ae71611816625c45d8849"><gtr:id>2c146feeef9ae71611816625c45d8849</gtr:id><gtr:otherNames>Coleman MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>56d8c5b6947f38.94332611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBB8FDF1-A0AF-4B32-A9C4-E12B45B6D587</gtr:id><gtr:title>Deletions within its subcellular targeting domain enhance the axon protective capacity of Nmnat2 in vivo.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d58a9a5ad825cb71ef07d1ae5f07ccce"><gtr:id>d58a9a5ad825cb71ef07d1ae5f07ccce</gtr:id><gtr:otherNames>Milde S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>54648c11edf900.19959252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31A6D06F-9E62-457C-8FB0-3D06721B6FBA</gtr:id><gtr:title>Significance of stroma in biology of oral squamous cell carcinoma.</gtr:title><gtr:parentPublicationTitle>Tumori</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2584bbff86644e52e360192a55e19060"><gtr:id>2584bbff86644e52e360192a55e19060</gtr:id><gtr:otherNames>Vucicevic Boras V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-8916</gtr:issn><gtr:outcomeId>5a957abf2705e0.98392669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66DD3A19-8CC2-42F0-9D97-14EC4B838A82</gtr:id><gtr:title>Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments.</gtr:title><gtr:parentPublicationTitle>Cancer &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40921e61f7b71eb633519b3ff4ba3425"><gtr:id>40921e61f7b71eb633519b3ff4ba3425</gtr:id><gtr:otherNames>Peck B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2049-3002</gtr:issn><gtr:outcomeId>58c7b47fd26530.34118340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C945D8CE-48E3-44E5-81E4-FD166C608CA1</gtr:id><gtr:title>Fatty acid uptake and lipid storage induced by HIF-1a contribute to cell growth and survival after hypoxia-reoxygenation.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6959c93799c3871fd5990a204551d2c8"><gtr:id>6959c93799c3871fd5990a204551d2c8</gtr:id><gtr:otherNames>Bensaad K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56af82de2ba854.29939882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>422A6498-7D8B-4532-8AE4-D4D4CDB1029F</gtr:id><gtr:title>dSarm/Sarm1 is required for activation of an injury-induced axon death pathway.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27bc01687302b65233cac85c7ce43213"><gtr:id>27bc01687302b65233cac85c7ce43213</gtr:id><gtr:otherNames>Osterloh JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>54648c1223bc27.86895416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA52962C-5FAA-4615-9102-D3A1593DA7B8</gtr:id><gtr:title>The axon-protective WLD(S) protein partially rescues mitochondrial respiration and glycolysis after axonal injury.</gtr:title><gtr:parentPublicationTitle>Journal of molecular neuroscience : MN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6391bc557e7e9aeb19d051f184e9d728"><gtr:id>6391bc557e7e9aeb19d051f184e9d728</gtr:id><gtr:otherNames>Godzik K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0895-8696</gtr:issn><gtr:outcomeId>54648c10d226b4.16108802</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0EE194D-6BA5-4064-96B5-37C23C58CA96</gtr:id><gtr:title>C13orf31 (FAMIN) is a central regulator of immunometabolic function.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32711005bbbc3c895889b86f934b0688"><gtr:id>32711005bbbc3c895889b86f934b0688</gtr:id><gtr:otherNames>Cader MZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>58c7b47f53ed56.88429662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4490BA1-C146-4D04-8C14-1D77290B6AE9</gtr:id><gtr:title>Mitochondria as a central sensor for axonal degenerative stimuli.</gtr:title><gtr:parentPublicationTitle>Trends in neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/107efa5889bf1ee6a7b1ec6a653aa623"><gtr:id>107efa5889bf1ee6a7b1ec6a653aa623</gtr:id><gtr:otherNames>Court FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0166-2236</gtr:issn><gtr:outcomeId>56d8c5b7091668.02341965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40779D63-8C80-4208-B150-98527AE0DFA1</gtr:id><gtr:title>Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3a6e5819e23ac730e2fc086c9ece34f"><gtr:id>c3a6e5819e23ac730e2fc086c9ece34f</gtr:id><gtr:otherNames>Chell V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>546f5109671943.32390730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E3A9903-4C78-4E08-8E2F-64CEDB70CD38</gtr:id><gtr:title>Absence of SARM1 rescues development and survival of NMNAT2-deficient axons.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e775577e058c629edaa52170e133fdc"><gtr:id>6e775577e058c629edaa52170e133fdc</gtr:id><gtr:otherNames>Gilley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d8c5b641a2c1.10272580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A3A0AAC-B303-44CC-9522-A48ED88A1133</gtr:id><gtr:title>MEK inhibitor U0126 reverses protection of axons from Wallerian degeneration independently of MEK-ERK signaling.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6a1d50ea11f9d6a6fc49721bd0ab613"><gtr:id>c6a1d50ea11f9d6a6fc49721bd0ab613</gtr:id><gtr:otherNames>Evans C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54648c11a03c63.54922945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18FAED2D-1CC2-4E8F-AE0C-B707918975F4</gtr:id><gtr:title>NMN Deamidase Delays Wallerian Degeneration and Rescues Axonal Defects Caused by NMNAT2 Deficiency In&amp;nbsp;Vivo.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4567fd8ee15a273550144bd1ab1c52af"><gtr:id>4567fd8ee15a273550144bd1ab1c52af</gtr:id><gtr:otherNames>Di Stefano M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn><gtr:outcomeId>58bd404856c7a8.16670136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E81CFD5E-D97E-4D62-864F-64A2A95F009E</gtr:id><gtr:title>Mechanisms of acquired resistance to ERK1/2 pathway inhibitors.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90c92f1ca52279657b6aff9f15ffdfcd"><gtr:id>90c92f1ca52279657b6aff9f15ffdfcd</gtr:id><gtr:otherNames>Little AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>546f4fca916313.15697646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52C4462B-A77E-4D50-BEC4-47D037005E90</gtr:id><gtr:title>Maternal DNA Methylation Regulates Early Trophoblast Development.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2d5a73be80a81960b21111c9c36c85e"><gtr:id>d2d5a73be80a81960b21111c9c36c85e</gtr:id><gtr:otherNames>Branco MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>56c1c2cc36d951.02517924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FCBE800-EBEB-4883-B166-A324905FA0A0</gtr:id><gtr:title>Age-related axonal swellings precede other neuropathological hallmarks in a knock-in mouse model of Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89a842625408aa64bfd1e37011f014ca"><gtr:id>89a842625408aa64bfd1e37011f014ca</gtr:id><gtr:otherNames>Marangoni M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>54648c11532663.00112000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F533270-BE9E-4B24-992A-60F87E5475EF</gtr:id><gtr:title>The role of MAPK signalling pathways in the response to endoplasmic reticulum stress.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6729b387bf4e554c2fee167548dc24df"><gtr:id>6729b387bf4e554c2fee167548dc24df</gtr:id><gtr:otherNames>Darling NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>546f510a42e8f6.55054748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C01C8BDD-2C18-403B-A591-8CB744040522</gtr:id><gtr:title>Knockdown of diacylglycerol kinase delta inhibits adipocyte differentiation and alters lipid synthesis.</gtr:title><gtr:parentPublicationTitle>Obesity (Silver Spring, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08e03efebfa0980c579cfa3efa21a5b0"><gtr:id>08e03efebfa0980c579cfa3efa21a5b0</gtr:id><gtr:otherNames>Lowe CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1930-7381</gtr:issn><gtr:outcomeId>pm_14832_22_23703849</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3E24CA5-7FC9-40E0-958F-31AC3449C84A</gtr:id><gtr:title>Dietary restriction protects from age-associated DNA methylation and induces epigenetic reprogramming of lipid metabolism.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d19cda99263b3af807171ba9339d36e0"><gtr:id>d19cda99263b3af807171ba9339d36e0</gtr:id><gtr:otherNames>Hahn O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>5a840bc23adcf6.67265485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6304BADE-DC15-4681-BDBA-E081882BFD82</gtr:id><gtr:title>Axonal trafficking of NMNAT2 and its roles in axon growth and survival in vivo.</gtr:title><gtr:parentPublicationTitle>Bioarchitecture</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d58a9a5ad825cb71ef07d1ae5f07ccce"><gtr:id>d58a9a5ad825cb71ef07d1ae5f07ccce</gtr:id><gtr:otherNames>Milde S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1949-0992</gtr:issn><gtr:outcomeId>56d8c5b6b4f351.27662870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99234A72-4E84-4828-8EAB-CCC9FC9E20E6</gtr:id><gtr:title>Mislocalization of neuronal tau in the absence of tangle pathology in phosphomutant tau knockin mice.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e775577e058c629edaa52170e133fdc"><gtr:id>6e775577e058c629edaa52170e133fdc</gtr:id><gtr:otherNames>Gilley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d8c5b5e4a132.38854444</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/B/000C0417</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>